tiprankstipranks
Trending News
More News >

Legend immunotherapy offers hope of cure for incurable blood cancer, NYT says

In a study involving 97 patients with advanced, treatment-resistant multiple myeloma, a third responded remarkably to a last-resort immunotherapy developed by Legend Biotech (LEGN). Their cancer disappeared and has not returned after five years — an unprecedented outcome in this incurable disease — and the results have prompted some oncologists to cautiously suggest the possibility of a “potential cure,” The New York Times’ Gina Kolata reports. The new study, reported Tuesday at the annual conference of the American Society of Clinical Oncology and published in The Journal of Clinical Oncology, was funded by Johnson & Johnson (JNJ), which has an exclusive licensing agreement with Legend Biotech. Shares of Legend Biotech are up 4.4% to $29.68 in early trading.

Don’t Miss TipRanks’ Half-Year Sale

Published first on TheFly – the ultimate source for real-time, market-moving breaking financial news. Try Now>>

Disclaimer & DisclosureReport an Issue

1